Examples of using Co-primary in English and their translations into German
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
Co-primary endpoints: ARR& SAD.
Mean number of micturitions per 24 hours(FAS) Co-primary.
Co-primary endpoint in Study 204.
Primary endpoint in Study 304; Co-primary endpoint in Study 204.
Mean number of incontinence episodes per 24 hours(FAS-I) Co-primary.
The co-primary endpoints are investigator-assessed PFS and OS.
Early morning motor function, assessed by UPDRS part III, and nocturnal sleep disturbances, measured by the modified Parkinson's Disease Sleep Scale(PDSS-2), were co-primary outcome measures.
The co-primary endpoints of PK and efficacy met their pre-specified criteria.
The second Phase 3 study in earlier line metastatic breast cancer, Study 301, was an open-label, randomized, study in patients(n=1102) with locally advanced or metastatic breast cancer to investigate the efficacy of HALAVEN monotherapy compared to capecitabine monotherapy in terms of OS andPFS as co-primary endpoint.
Co-primary endpoints: ACR 20 at Week 24 and change from baseline in mTSS at Week 52.
As a secondary endpoint in dialysis patients, and a co-primary endpoint in non-dialysis patients, the ability of Fexeric to increase iron stores was also evaluated.
In particular, in a post-hoc analysis in 2,172 patients(17% of the total CURE population) who underwent stent placement(Stent-CURE), the data showed that clopidogrel compared to placebo, demonstrated a significant RRR of 26.2% favouring clopidogrel for the co-primary endpoint(CV death, MI, stroke) and also a significant RRR of 23.9% for the second co-primary endpoint CV death, MI, stroke or refractory ischaemia.
Table 1: Co-primary and Selected Secondary Efficacy Endpoints at End of Treatment for Pooled Studies.
The co-primary efficacy endpoints of the study were overall survival(OS) and progression-free survival PFS.
Table 2: Co-primary and Selected Secondary Efficacy Endpoints at End of Treatment for Studies 046, 047 and 074.
The co-primary endpoints were death from any cause and the first occurrence of re-infarction, stroke or death.
The co-primary endpoints of the study were overall survival and progression free survival as assessed by trial investigators.
The two co-primary endpoints were percent change from baseline body weight and the proportion of subjects achieving≥5% total decreased body weight.
In addition to the co-primary endpoint measures, benefit was also assessed using time to opiate use for cancer pain, time to initiation of cytotoxic chemotherapy, time to deterioration in ECOG performance score by.
Analysis of the other co-primary endpoint showed that patients taking alemtuzumab experienced at least a 70 percent reduction in the risk for progression of clinically significant disability when compared to patients treated with interferon beta-1a.
Analysis of the first co-primary endpoint showed that patients taking alemtuzumab experienced at least a 73 percent reduction in the risk for relapse after three years of follow up when compared to patients treated with interferon beta-1a.
While a numerical improvement for the co-primary endpoint of overall survival(OS) was observed, statistical significance was not met at this interim analysis, and the study will continue as planned with final OS results expected next year.
The first co-primary endpoint was the proportion of patients having a rescue free bowel movements(RFBMs) within 4 hours of the first dose administration and the second the percentage of active injections resulting in any RFBM within 4 hours during the double-blind phase.